BioPharma APAC

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to address critical unmet medical needs in neurological, psyc...

January 17, 2023 | News

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mass...

January 16, 2023 | News

FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug...

January 09, 2023 | News

FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial

Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with ...

December 23, 2022 | News

STADA partners with BIAL to bring Ongentys to Parkinson’s patients in Australia

STADA receives from BIAL exclusive rights to market and distribute Ongentys (opicapone) capsules in Australia STADA Specialty Head Bryan Kim: "Ongentys ...

December 19, 2022 | News

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression ...

December 15, 2022 | News

Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases

Washington University is world leading in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases. The two organizations ...

December 15, 2022 | News

Over £175 million for cutting-edge genomics research to help boost diagnosis treatment for patients

£105 million to speed up diagnosis of rare genetic diseases in newborns, potentially resulting in life-saving interventions for thousands of babies...

December 15, 2022 | News

HUMAN celebrates its 50th anniversary

From reagent specialist to global player with a broad network of long-standing distribution partners in more than 160 countries • Covering a compre...

December 05, 2022 | News

1 in 3 women suffer from Iron Deficiency symptoms including tiredness and dizziness

Launches 'Sangobion Anaemia meter', a convenient online tool that empowers consumers to screen themselves for the risks of iron deficiency, the most c...

November 28, 2022 | News

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver more Medicines to Patients Faster

Company aims to launch one new product or indication every 1.5 years on average, bolstered by external innovation Phase III assets xevinapant and evobru...

November 23, 2022 | News

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation ...

November 22, 2022 | News

Swedish and Jordanian royalty inaugurate Elekta radiation therapy devices for cancer and brain disease

Dignitaries from Sweden and Jordan attended the inauguration of two of Elekta’s (EKTA-B.ST) cancer care technologies, including an advanced linear ac...

November 18, 2022 | News

Research on neural dynamics wins 2022 Eppendorf & Science Prize

By comparing the activation of neurons in multiple deep brain regions, she identifies differences between them that point to the role each region plays in ...

November 04, 2022 | News

Stay Connected